INOVIQ : Updated Investor Presentation

Investor Presentation

ASX: IIQ | 6 April 22

This presentation has been prepared by INOVIQ Limited ("INOVIQ" or the "Company") based on

information available to it as at the date of this presentation. This presentation contains general and background information about the Company's activities current as at the date of the

presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision and does not contain all information about the Company's assets and liabilities, financial position and

performance, profits and losses, prospects, and the rights and liabilities attaching to the

Company's securities necessary to make an investment decision. The information in this presentation should be read in conjunction with the Company's other periodic and continuous

disclosure announcements lodged with the Australian Securities Exchange (ASX), available atwww.asx.com.au. The information in this presentation is based on the Company's own

information and estimates and has not been independently verified. The Company is not responsible for providing updated information and assumes no responsibility to do so. Any investment in the Company should be considered speculative and there is no guarantee that they will make a return on capital invested, that dividends would be paid, or that there will be an increase in the value of the investment in the future.

This Presentation may contain certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to

identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including INOVIQ or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of INOVIQ cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

Introduction

There is a major unmet need for non-invasive, accurate and reliable diagnostic tests for earlier detection of cancer and other diseases.

INOVIQ's technologies enable earlier and more accurate detection - improving treatment options, patient outcomes & survival.

Company Overview

INOVIQ Ltd

• • Developing diagnostic and exosome-based solutions for cancer and other diseases

• • Proprietary technology platforms for biomarker isolation and detection

• • Products in-market for bladder cancer & exosome research

• • Multi-product pipeline for detection and monitoring of breast, ovarian and other cancers targeting US$11b global markets

  Financial information (ASX:IIQ)
  Ordinary shares	92,018,702
  Share price (1/4/22)	A$0.880
  Market capitalisation	A$81.0m
  Cash position (31/12/21)	A$18.6m
  Ave monthly cash burn (Q2 FY22)	A$611.7k
  Top 20 Shareholders (1/4/22)	34.6%

• • Compelling early data for detection and monitoring breast and ovarian cancers

• • Nearing multiple key inflection points

• • Strong cash position of $18.6m to fund operations and pipeline development

Share price performance

BEFORE DIAGNOSIS

AFTER DIAGNOSIS

Genetic tests to predict the risk of developing a cancer

Tests for early detection of cancer in asymptomatic people

Existing test examples

BRCA1 test

Screening mammography;

PSA test

IIQ pipeline

N/A

OCRF-7 OC test

Tests for confirming a diagnosis of cancer

CT scan, MRI, PET, TVUS,

ROCA, OVA1

Tests for staging and triage to treatment

BRACAnalysis CDx®

Tests for monitoring treatment response and disease recurrence

CA125 test, CA15.3 test

future focus

future focus

SubB2M OC test SubB2M BC test